Portland, OR Clinical Trials Report — June 2026

For Portland residents considering participation in clinical research, June 2026 presents a mix of immediate opportunities and significant new studies. Across Portland, OR, a total of 975 clinical trials are currently recruiting participants at 318 research facilities. However, prompt action is crucial for many, as 48 trials are scheduled to close their enrollment within the next 90 days.

Among these rapidly closing studies, 3 trials are still accepting healthy volunteers. This offers a valuable chance for individuals without specific health conditions to contribute to medical advancements before these opportunities conclude.

New Research Frontiers in Obesity and Migraine

This month, Portland welcomed 11 new clinical trials, a slight decrease from the 12 trials that opened in May 2026. These new studies bring cutting-edge research to the city, including several notable Phase 3 drug trials from major sponsors.

• Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring a significant Phase 3 study, NCT07654361, "Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)." This global, randomized, placebo-controlled study aims to investigate the long-term efficacy, safety, and tolerability of aleniglipron once daily compared with placebo for weight management.
• Also from Gasherbrum Bio, Inc., another Phase 3 trial, NCT07654374, "A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)," is recruiting. This randomized, double-blind, placebo-controlled study will evaluate aleniglipron's efficacy, safety, and tolerability in participants living with overweight or obesity and Type 2 Diabetes Mellitus over 76 weeks.
• Kallyope Inc. is initiating two important Phase 3 studies focused on migraine treatment. The first, NCT07645924, "A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine," is a double-blind, randomized, multicenter evaluation of elismetrep compared with placebo.
• The second Kallyope Inc. study, NCT07674654, "A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," will assess the safety and tolerability of intermittent use of elismetrep for acute migraine attacks.

The new trials this month cover a range of conditions, with a particular focus on weight management. Conditions addressed by new trials include:

• Obesity (2 trials)
• Overweight (2 trials)
• Chronic weight management (2 trials)
• Head and neck cancer (1 trial)
• Hearing loss (1 trial)
• Malignant head and neck neoplasm (1 trial)
• Melanoma (1 trial)
• Migraine (1 trial)
• Parkinson's disease with freezing of gait (1 trial)
• Perinatal substance use (1 trial)

Drug trials account for 4 of the new studies, alongside 5 "OTHER" type trials, 2 behavioral studies, and 1 device trial. Industry sponsors, including Gasherbrum Bio, Inc. and Kallyope Inc., are leading 5 of these new studies, with academic institutions and federal entities also contributing significantly.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are consistent opportunities to contribute to research. Of the 11 new trials launched this month, 3 are actively seeking healthy volunteers. Overall, Portland currently has 71 clinical trials recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Leading Research Facilities in Portland

Portland is home to several prominent research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Oregon Health and Science University (195 trials)
• Oregon Health & Science University (148 trials)
• Providence Portland Medical Center (124 trials)
• Providence Saint Vincent Medical Center (94 trials)
• OHSU Knight Cancer Institute (38 trials)
• Research Site (35 trials)
• Providence St. Vincent Medical Center (22 trials)
• Legacy Good Samaritan Hospital and Medical Center (22 trials)
• Oregon Health Sciences University (21 trials)
• Kaiser Permanente Northwest (19 trials)
• Legacy Emanuel Children's Hospital (19 trials)
• VA Portland Health Care System, Portland, OR (18 trials)

Oregon Health and Science University (OHSU) and its various entities, including the OHSU Knight Cancer Institute, collectively represent a substantial portion of the city's research activity. Providence Health & Services facilities also contribute significantly to the local research landscape.

Impending Deadlines for Specific Conditions

Patients managing specific health conditions should note the trials nearing their enrollment deadlines. Conditions with trials closing soon include:

• Prostate cancer (2 trials)
• Advanced breast cancer (2 trials)
• Duchenne muscular dystrophy (2 trials)
• Tricuspid regurgitation (2 trials)
• Ovarian cancer (2 trials)
• Breast cancer (2 trials)
• Aortic insufficiency (1 trial)
• Antiphospholipid syndrome (aps) (1 trial)
• Advanced malignant neoplasm (1 trial)
• Atopic dermatitis (1 trial)

Expanding Your Search: Nearby Options

While Portland offers a wide array of clinical trial opportunities, individuals in Oregon may also find options in other communities. Grants Pass, for example, has 1 active trial, offering an alternative for those willing to travel within the state.

Participation in clinical trials is open to a diverse range of individuals. All 11 new trials launched this month include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. No new trials are exclusively for children, females, or males. Academic institutions and industry sponsors are both driving significant research efforts in Portland, with OHSU Knight Cancer Institute sponsoring 3 new trials and Kallyope Inc. and Gasherbrum Bio, Inc. each sponsoring 2 new trials this month.

As Portland's research community continues to innovate, these diverse opportunities will advance medical understanding and offer new treatment avenues for patients and healthy volunteers alike.